BVS
HealthcareBioventus Inc. · Medical - Devices · $890M
What is Bioventus Inc.?
Bioventus Inc. is a small-cap medical device company focused on treatments that support the body's natural healing processes. Operating across the United States and internationally, it serves orthopedic and surgical care markets.
Bioventus develops and commercializes products across three core areas: pain treatments, surgical solutions, and restorative therapies. Its pain segment centers on non-surgical joint injections and peripheral nerve stimulation. Surgical solutions include bone graft substitutes and ultrasonic devices used in spinal and orthopedic procedures. Restorative therapies cover fracture care systems, skin allografts, wound healing products, and advanced rehabilitation devices. The company sells to physicians across sports medicine, spine, trauma, and neurosurgery settings.
Bioventus was founded in 2011 and is headquartered in Durham, North Carolina.
- Non-surgical joint pain injection therapies
- Peripheral nerve stimulation products
- Bone graft substitutes for spinal and orthopedic surgery
- Ultrasonic bone sculpting and tissue debridement devices
- Restorative therapies including fracture care and wound healing
Is BVS a Good Stock to Buy?
UQS Score rates BVS as Below Average overall, reflecting meaningful challenges across several key quality dimensions.
Among the five pillars, Valuation stands out as Attractive, suggesting the stock may be priced at a discount relative to its fundamentals. Quality and Growth both register as Neutral, indicating neither a clear drag nor a standout advantage in those areas.
Moat and Risk are both rated Weak, pointing to limited competitive differentiation and elevated uncertainty — two factors that weigh heavily on the overall composite score.
Pro members can view the complete pillar breakdown and underlying financial metrics to form a more complete picture of BVS. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does BVS pay dividends?
No — Bioventus Inc. does not currently pay a dividend.
Bioventus does not currently pay a dividend. For a company at this stage of development, retaining capital to fund product commercialization, clinical development, and potential acquisitions is a common strategic choice. Income-focused investors should be aware that BVS does not offer a yield at this time.
When does BVS report earnings?
Bioventus reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's Neutral Growth and Quality pillar ratings suggest results have been mixed — neither consistently outperforming nor sharply deteriorating. Investors should monitor revenue trends and profitability progress across reporting periods.
For the most recent quarter's results and guidance, visit Bioventus's investor relations page directly.
BVS Price History
-21.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Bioventus Inc.?
Based on Bioventus Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
BVS Long-term Outlook
The fundamental outlook for BVS is cautious. Neutral Growth suggests the business has some forward momentum, but Weak Moat and Weak Risk ratings indicate that sustaining that growth against competitive and operational headwinds remains a challenge. The Attractive Valuation pillar may reflect market skepticism already priced in, rather than a straightforward opportunity. Investors weighing a longer-term position should consider whether the company can strengthen its competitive positioning over time.
Growth drivers
- Expanding orthopedic and surgical addressable markets
- Commercialization of restorative therapy and wound care products
- Potential for international revenue growth beyond the US market
Key risks
- Weak competitive moat in a crowded medical device landscape
- Elevated operational and financial risk given small-cap profile
- Execution risk in scaling multiple product categories simultaneously
BVS vs Peers
Bioventus operates in a competitive segment of the medical device space, facing peers with varying specializations across neurology, bone health, and surgical care.
CeriBell focuses on rapid EEG monitoring for neurological conditions, occupying a distinct niche from Bioventus's orthopedic and healing-focused portfolio.
BrainsWay specializes in deep transcranial magnetic stimulation for psychiatric and neurological disorders, targeting a different therapeutic area than Bioventus.
SI-BONE concentrates on minimally invasive surgical implants for sacropelvic conditions, overlapping with Bioventus in the orthopedic surgical space.
Frequently Asked Questions
What does Bioventus do?
Bioventus develops and sells medical treatments designed to support the body's natural healing. Its products span pain management injections, surgical bone grafting solutions, ultrasonic surgical devices, and restorative therapies for fractures and chronic wounds. The company primarily serves orthopedic and surgical specialists across clinics, ambulatory surgical centers, and hospitals.
Does BVS pay dividends?
No, Bioventus does not currently pay a dividend. The company appears to prioritize reinvesting capital into its product pipeline and commercial operations rather than returning cash to shareholders through distributions.
When does BVS report earnings?
Bioventus follows a standard quarterly earnings cadence for US-listed companies. For exact dates and the most recent financial results, check the investor relations section of the Bioventus website.
Is BVS a good stock to buy?
UQS Score rates BVS as Below Average, driven by Weak Moat and Weak Risk pillar ratings. The Valuation pillar is Attractive, which may interest contrarian investors, but the overall profile suggests meaningful uncertainty. Reviewing the full pillar breakdown on UQS Score can help inform a more complete assessment.
Is BVS overvalued?
Based on the UQS Valuation pillar, BVS is rated Attractive — meaning the stock does not appear overvalued relative to its fundamentals. However, an attractive price alone does not offset the Weak ratings in Moat and Risk, which reflect real business-level challenges.
How does BVS compare to its competitors?
Among the peers tracked by UQS Score — including SI-BONE, CeriBell, and BrainsWay — each company occupies a distinct niche within medical devices. SI-BONE is the closest overlap in orthopedic surgery, while CeriBell and BrainsWay focus on neurological applications. Pro members can view side-by-side UQS pillar comparisons.
What is BVS's market cap bracket?
Bioventus is classified as a small-cap company. This means it carries higher volatility and liquidity risk compared to large- or mega-cap peers, but may also offer greater upside potential if the business executes on its growth strategy.
Who founded Bioventus?
Bioventus was founded in 2011. Detailed information about the founding team is publicly available through the company's official website and SEC filings, which provide the most accurate historical record.
Is BVS a long-term quality investment?
As a long-term quality indicator, BVS's Below Average UQS Score — particularly its Weak Moat rating — raises questions about durable competitive advantage. Long-term quality investing typically favors companies with strong moats and manageable risk profiles, areas where BVS currently falls short.
What is the main competitive advantage of Bioventus?
Bioventus's breadth across pain, surgical, and restorative therapy categories gives it exposure to multiple orthopedic market segments. However, the UQS Moat pillar rates this advantage as Weak, suggesting the company has not yet established a clearly defensible position relative to peers.
What sector does BVS belong to?
Bioventus operates in the Healthcare sector, specifically within the medical devices and orthopedic treatments space. You can explore other [healthcare stocks scored by UQS](/sector/healthcare) to compare BVS against sector peers.
Unlock Full BVS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across all five dimensions
- ✓Access detailed financial metrics behind each rating
- ✓Compare BVS side-by-side with orthopedic device peers
- ✓Track pillar changes as new earnings data arrives
- ✓Screen for higher-quality small-cap healthcare alternatives
Pro Analysis
BVS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Oct 4, 2026 | 12.0 | 0.0 | 26.0 | 0.0 | 36.9 | 0.0 | -37.0 |
| Jul 30, 2026 | 49.0 | 62.1 | 26.0 | 52.3 | 27.7 | 82.3 | -0.4 |
| Jul 25, 2026 | 49.4 | 62.1 | 26.0 | 52.4 | 27.7 | 84.9 | -0.2 |
| Jul 24, 2026 | 49.6 | 62.1 | 26.0 | 52.4 | 27.7 | 86.0 | +0.1 |
| Jul 23, 2026 | 49.5 | 62.1 | 26.0 | 52.4 | 27.7 | 85.5 | +0.1 |
| Jul 22, 2026 | 49.4 | 62.1 | 26.0 | 52.4 | 27.7 | 84.8 | -0.2 |
| Jul 21, 2026 | 49.6 | 62.1 | 26.0 | 52.4 | 27.7 | 86.3 | +0.3 |
| Jul 18, 2026 | 49.3 | 62.1 | 26.0 | 52.4 | 27.7 | 84.7 | +0.1 |
| Jul 17, 2026 | 49.2 | 62.1 | 26.0 | 52.4 | 27.7 | 83.9 | -0.2 |
| Jul 16, 2026 | 49.4 | 62.1 | 26.0 | 52.4 | 27.7 | 85.1 | -0.2 |
BVS — Pillar Breakdown
Quality
— 0.0/100 (25%)Bioventus Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Ability to convert revenue into operating profit.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Bioventus Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Analyst consensus for future revenue growth.
Risk
— 36.9/100 (15%)Bioventus Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Bioventus Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 26/100 (25%)Bioventus Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BVS.
Score Composition
Financial Data
More Stock Analysis
How is the BVS UQS Score Calculated?
The UQS (Unified Quality Score) for Bioventus Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Bioventus Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Bioventus Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.